NCT02634515已完成1 期
A Randomized, Single-center, Double-blind, 2-period Crossover, Euglycemic Glucose Clamp Study in Healthy Subjects to Demonstrate PK and PD Equivalence of Julphar Insulin R and Huminsulin® Normal
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- PD: AUCGIR.0-last, area under the glucose infusion rate curve from 0 hours until the end of the glucose clamp
研究概览
简要总结
This study in healthy volunteers aimed to demonstrate similar PK and PD properties of the new short-acting human soluble insulin, Julphar Insulin R, and the already approved reference insulin, Huminsulin® Normal. The trial participants received both study treatments on two separate dosing days.
详细描述
The daily injection of insulin is a necessity for many patients with diabetes mellitus in order to treat hyperglycemia. Julphar Insulin R and Huminsulin® Normal are both soluble insulins intended for subcutaneous administration and consist of a neutral solution containing recombinant human insulin as the active ingredient. The new insulin, Julphar Insulin R is biosimilar to Huminsulin® Normal. Demonstration of bioequivalence from a PK and PD perspective of the two insulins are necessary to achieve market approval for Julphar Insulin R.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
- •Healthy male or female subjects.
- •Age between 18 and 55 years, both inclusive.
- •Body Mass Index (BMI) between 18.5 and 28.0 kg/m^2, both inclusive.
- •Fasting plasma glucose (FPG) ≤5.6 mmol/L (100 mg/dL).
排除标准
- •Known or suspected hypersensitivity to trial product(s) or related products.
- •Receipt of any IMP within 3 months prior to screening.
- •Any history or presence of a life threatening disease (i.e., cancer except basal cell skin cancer or squamous cell skin cancer), or of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurological, musculoskeletal, articular, psychiatric, systemic, ocular, gynaecologic (females), or infectious disease, or signs of acute illness as judged by the Investigator.
- •Surgery within 12 weeks before the start of the study or blood donation of more than 500 mL (or considerable blood loss) or plasma donation within the last 3 months.
- •Increased risk of thrombosis, e.g., subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.
- •Haemoglobin < 8.0 mmol/L (male) or < 6.4 mmol/L (female), total leukocyte count < 3.0 x 10^9/L, thrombocytes < 100 x 10^9/L, serum creatinine levels ≥ 126 µmol/L (male) or ≥ 111 µmol/L (female), alanine aminotransferase (ALT) > 2 x the upper limit of normal (ULN), bilirubin > 3 x ULN, alkaline phosphatase > 2 x ULN.
- •Supine blood pressure (BP) at screening (after resting for 5 minutes in a supine position) outside the range of 90 to 140 mmHg for systolic BP or 50 to 90 mmHg for diastolic BP (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial) and/or resting supine pulse < 50 beats per minute.
- •Clinically significant abnormal standard 12-lead ECG after 5 minutes resting in a supine position at screening, as judged by the Investigator.
- •Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety.
- •Subject known to be positive for Hepatitis Bs antigen (HBsAg) or Hepatitis C antibodies (or diagnosed with active hepatitis according to local practice) or test positive at screening for human immunodeficiency virus Type 1 (HIV-1) antibodies, HIV Type 2 (HIV 2) antibodies, or HIV-1 antigen according to locally used diagnostic testing.
- •History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
- •Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.
- •Any medication (prescription and non-prescription drugs) within 14 days before first trial drug administration, with the exception of stable treatment with thyroid hormones, paracetamol for occasional use to treat pain, and if female, with the exception of hormonal contraception or menopausal hormone replacement therapy.
- •Significant history of alcoholism or drug/chemical abuse as per Investigator's judgement or a positive result in the urine drug/alcohol screen at the screening visit or consuming more than 21 units of alcohol per week (1 unit of alcohol equals approximately 330 mL of beer, 1 glass of wine (120 mL), or 40 mL spirits).
- •Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) who is not able or willing to refrain from smoking and use of nicotine substitute products 1 day before and during the inpatient period/trial.
- •Subject with mental incapacity or language barriers precluding adequate understanding or cooperation or who, in the opinion of the Investigator or their general practitioner, should not participate in the trial.
- •Potentially noncompliant or uncooperative during the trial, as judged by the Investigator.
- •Female who is pregnant, breast feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures are defined as surgical sterilisation, implants, injectables, combined oral contraceptives, hormonal intrauterine device, sexual abstinence, or vasectomised partner).
研究组 & 干预措施
Julphar Insulin R
Experimental
Julphar Insulin R, soluble human insulin, biosimilar, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
干预措施: Julphar Insulin R (soluble human insulin, biosimilar) (Drug)
Huminsulin® Normal
Active Comparator
Huminsulin® Normal, soluble human insulin, reference, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
干预措施: Huminsulin® Normal (soluble human insulin, reference) (Drug)
结局指标
主要结局
PD: AUCGIR.0-last, area under the glucose infusion rate curve from 0 hours until the end of the glucose clamp
时间窗: 12 hours
primary endpoint according EMA guideline
PK: AUCins.0-12h, area under the serum insulin concentration time curve from 0 to 12 hours
时间窗: 12 hours
primary endpoint according EMA guideline
PK: Cins.max, maximum serum insulin concentration
时间窗: 12 hours
primary endpoint according EMA guideline
PD: GIRmax, maximum glucose infusion rate
时间窗: 12 hours
primary endpoint according EMA guideline
次要结局
- PK: MRT, mean residence time(12 hours)
- PK: V/F, volume of distribution(12 hours)
- PK: CL/F, total body clearance(12 hours)
- Adverse events(from first trial drug administration until final examination (up to 30 days for each patient))
- PK: AUCins.0-6h,area under the serum insulin concentration time curve from 0 to 6 hours(6 hours)
- PK: λz, terminal elimination rate constant of insulin(12 hours)
- PK: t50%-late, time to serum insulin decreased to 50%, respectively of maximum serum insulin concentration(12 hours)
- PD: tGIRmax, time to maximum glucose infusion rate curve(12 hours)
- PD: tGIR50%-early, time to GIR increased to 50%, respectively of maximum GIR value(12 hours)
- Laboratory safety variables (haematology, biochemistry, and urinalysis)(from screening until the final examination (up to 58 days for each patient))
- Assessment of local tolerability at the injection site(from first trial drug administration until the final examination (up to 58 days for each patient))
- PK: t50%-early, time to serum insulin increased to 50%, respectively of maximum serum insulin concentration(12 hours)
- PK: t½, terminal serum elimination half-life calculated as t½=ln2/λz(12 hours)
- PD: AUCGIR0-4h, AUCGIR0-6h, AUCGIR6-last, areas under the glucose infusion rate curve in the indicated time-intervals(12 hours)
- PD: tGIR50%-late, time to GIR decreased to 50%, respectively of maximum GIR value(12 hours)
- Vital signs recordings(from screening until the final examination (up to 58 days for each patient))
- PK: AUCins.0-4h,area under the serum insulin concentration time curve from 0 to 4 hours(4 hours)
- PK: AUCins.6-12h, area under the serum insulin concentration time curve from 6 to 12 hours(12 hours)
- PK: AUCins.0-infinity, area under the serum insulin concentration time curve from 0 (dosing) to infinity(12 hours)
- PK: tmax, time to maximum serum insulin concentration(12 hours)
- PD: onset of action - time from trial product administration until blood glucose concentration has decreased at least 0.3 mmol/L (5 mg/dL) from baseline(12 hours)
- Hypoglycaemic events(from first trial drug administration until the final examination (up to 30 days for each patient))
- Physical examination findings(from screening until the final examination (up to 58 days for each patient))
- Electrocardiograms(from screening until the final examination(up to 58 days for each patient))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® BasalDiabetes MellitusNCT02634528Julphar Gulf Pharmaceutical Industries85
已完成
1 期
Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil IIIDiabetes MellitusNCT02631928Julphar Gulf Pharmaceutical Industries73
已完成
1 期
A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced XgevaHealthy VolunteersNCT05299073mAbxience Research S.L.257
已完成
1 期
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy VolunteersHealthy MaleNCT01651234Green Cross Corporation48
Unknown
1 期
A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and USlicensed Avastin®.Healthy VolunteersNCT04408989mAbxience Research S.L.114